<?xml version="1.0" encoding="UTF-8" ?>
<?xml-stylesheet type="text/xsl" href="https://blogs.mercola.com:443/utility/FeedStylesheets/rss.xsl" media="screen"?><rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:wfw="http://wellformedweb.org/CommentAPI/"><channel><xhtml:meta xmlns:xhtml="http://www.w3.org/1999/xhtml" name="robots" content="noindex" /><title>Opioid Manufacturers Outed for Being Their Own Competitor; Now Want to Cash In on Treatment for the Addiction</title><link>https://blogs.mercola.com:443/sites/vitalvotes/archive/2018/09/10/opioid-manufacturers-outed-for-being-their-own-competitor-now-want-to-cash-in-on-treatment-for-the-addiction.aspx</link><description>Just when you thought the tale of the opioid epidemic couldn&amp;rsquo;t get any worse, the billionaire owners of Purdue Pharma, which created OxyContin, have been outed for double-dipping on the crisis. Or, perhaps you should call it triple-dipping, as it</description><dc:language>en</dc:language><generator>CommunityServer 2008.5 SP1 (Debug Build: 31106.3070)</generator></channel></rss>